The value of immunophenotyping hepatocellular adenomas: Consecutive resections at one UK centre

Histopathology

Volumn 62, Issue 3, 2013, Pages 431-445

  Bellamy, Christopher O C ^a   Maxwell, R Scott ^a   Prost, Sandrine ^a   Azodo, Ijeoma A ^b   Powell, James J ^b   Manning, Jonathan R ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Focal nodular hyperplasia; Hepatocellular adenoma; Hepatocellular carcinoma; Liver; Pathology

Indexed keywords

ALCOHOL; AZATHIOPRINE; CD34 ANTIGEN; DANAZOL; FATTY ACID BINDING PROTEIN; GLUTAMATE AMMONIA LIGASE;

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LIVER ADENOMA; LIVER FOCAL NODULAR HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM; VEIN DISEASE;

ADENOMA, LIVER CELL; ADULT; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOPHENOTYPING; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84872648701     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12011     Document Type: Article

References (36)

1. Bluteau O, Jeannot E, Bioulac-Sage P et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 2002; 32; 312-315.
2. Bioulac-Sage P, Laumonier H, Couchy G et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50; 481-489.
3. Zucman-Rossi J, Jeannot E, Nhieu JT et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43; 515-524.
4. Rebouissou S, Amessou M, Couchy G et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457; 200-204.
5. Nault JC, Fabre M, Couchy G et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J. Hepatol. 2012; 56; 184-191.
6. Pilati C, Amessou M, Bihl MP et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 2011; 208; 1359-1366.
7. Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46; 740-748.
8. Bioulac-Sage P, Laumonier H, Rullier A et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int. 2009; 29; 459-465.
9. Dokmak S, Paradis V, Vilgrain V et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137; 1698-1705.
10. Paradis V, Benzekri A, Dargere D et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004; 126; 1323-1329.
11. Paradis V, Champault A, Ronot M et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007; 46; 140-146.
12. Ronot M, Bahrami S, Calderaro J et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011; 53; 1182-1191.
13. van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, Ijzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J. Hepatol. 2011; 55; 120-125.
14. Sakellariou S, Al-Hussaini H, Scalori A et al. Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study. Histopathology 2012; 60; E58-E65.
15. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60; 85-89.
16. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch. Surg. 1994; 129; 712-717.
17. Kim DH, Kim SU, Nam DH et al. A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. Korean J. Intern. Med. 2009; 24; 147-152.
18. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod. Pathol. 2008; 21; 491-497.
19. Paradis V, Zalinski S, Chelbi E et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49; 851-859.
20. Davis M, Portmann B, Searle M, Wright R, Williams R. Histological evidence of carcinoma in a hepatic tumor associated with oral-contraceptives. Br. Med. J. 1975; 4; 496-498.
21. Ferrell LD. Hepatocellular-carcinoma arising in a focus of multilobular adenoma-a case-report. Am. J. Surg. Pathol. 1993; 17; 525-529.
22. Larson KA, Weber SM, Fong Y, Blumgart LH. Malignant transformation of hepatic adenoma with recurrence after resection. HPB (Oxford) 2002; 4; 139-143.
23. Hechtman JF, Raoufi M, Fiel MI et al. Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear beta-catenin and glutamine synthetase positivity: case report and review of the literature. Am. J. Surg. Pathol. 2011; 35; 927-932.
24. Bioulac-Sage P, Rebouissou S, Cunha AS et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128; 1211-1218.
25. Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver-a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am. J. Surg. Pathol. 1999; 23; 1441-1454.
26. Breiman L. Random forests. Mach. Learn. 2001; 45; 5-32.
27. Liaw A, Wiener M. Classification and regression by randomForest. R News 2002; 2; 18-22.
28. Bioulac-Sage P, Laumonier H, Sa Cunha A, Balabaud C. Hepatocellular adenomas. Liver Int. 2009; 29; 142.
29. Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J. Gastroenterol. 2007; 13; 2649-2654.
30. Shirahama T, Skinner M, Cohen AS. Heterogenous participation of the hepatocyte population in amyloid protein Aa synthesis. Cell Biol. Int. Rep. 1984; 8; 849-856.
31. Miura K, Takahashi Y, Shirasawa H. Immunohistochemical detection of serum amyloid A protein in the liver and the kidney after casein injection. Lab. Invest. 1985; 53; 453-463.
32. Bioulac-Sage P, Cubel G, Balabaud C. Pathological diagnosis of hepatocellular adenoma in clinical practice. Diagn. Histopathol. 2011; 17; 521-529.
33. Van der Borght S, Libbrecht L, Katoonizadeh A et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007; 51; 855-856.
34. Witjes CD, Ten Kate FJ, van Aalten SMet al. Hepatocellular adenoma as a risk factor for hepatocellular carcinoma in a non-cirrhotic liver: a plea against. Gut 2012 E-pub ahead of print, 25 April.
35. McCaughan GW, Bilous MJ, Gallagher ND. Long-term survival with tumor regression in androgen-induced liver tumors. Cancer 1985; 56; 2622-2626.
36. Westaby D, Portmann B, Williams R. Androgen related primary hepatic tumors in non-Fanconi patients. Cancer 1983; 51; 1947-1952.